Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
128794-94-5
Molecular formula
C23H31NO7
Molecular weight
433.5 g/mol
Drug class
Antimetabolite immunosuppressantprodrug of mycophenolic acid (MPA)
Mechanism of action
After absorption, mycophenolate mofetil is hydrolysed to mycophenolic acid, a selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This inhibits de-novo guanosine nucleotide synthesis and suppresses proliferation of T and B lymphocytes.
Indications / reported uses
Prophylaxis of organ rejection in adult and paediatric recipients aged 3 months and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants; not a stand-alone treatment for graft-versus-host disease or psoriasis
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Mycophenolate Mofetil Environmental Risk Assessment (ERA) (the Mycophenolate Mofetil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.